Axolabs
Jochen Deckert has extensive experience in the field of biology, currently serving as the Associate Director and Head of Biology at Axolabs GmbH since January 2012, following roles as Associate Director, Principal Scientist, and Senior Scientist within the same company. Prior to this, Jochen Deckert was a Scientist at Roche Kulmbach GmbH from August 2008 to October 2011 and completed a post-doctoral fellowship at the Max-Planck-Institut für Biophysikalische Chemie between February 2007 and July 2008. Educational credentials include a Dr. rer. nat. in Biology and a Master of Science in Molecular Biology from The University of Göttingen, along with a Dipl. Ing. in Biotechnology from Fachhochschule Weihenstephan Freising.
This person is not in any teams
Axolabs
Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world’s leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2024. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.